10.28.25 -- Targeting GRIN Genes To Treat Neurodevelopment Disorders

Devoting early-phase resources for solid form understanding and screening during a drug’s development lifecycle is critical, as doing so can help save time and resources on the path to market.

Insights and case studies demonstrate how a tailored, stepwise testing approach can effectively detect, quantify, and control nitrosamine impurities while maintaining cost efficiency.

Discover proven strategies to optimize cell line development workflows and reduce timelines without compromising quality. See how integrated platforms support higher-yield, faster CLD decisions.

Assimilate how the recently described cell line development paradigm shift can extend to the development of bispecific monoclonal antibody-producing cell substrates.

To enable comprehensive evaluation of therapies targeting both primary and metastatic tumors, we've developed dual-disease xenograft models using bioluminescence imaging (BLI).

Learn how a multi-step, variant-aware approach to CRISPR-based guide RNA selection systematically reduces off-target risk at each stage, giving researchers greater confidence in their work.

Explore how Prometheus Panta was used to assess multiple developability characteristics in Merck's mAb therapeutics and to gain deeper insight into the quality attributes of their candidates.

Spray dry technology is being leveraged to create shelf-stable, dry-powder vaccines to treat and prevent the spread of tuberculosis which could significantly improve our global response to disease.